RESUMEN
BACKGROUND: Diethylene glycol (DEG) is an industrial solvent with many uses, including brake fluids. It has also caused mass poisonings after use as an inappropriate substitute for propylene glycol or glycerin, though individual ingestions are rare. Like other toxic alcohols, DEG is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase, with toxicity likely mediated by the resulting metabolites. Fomepizole, an alcohol dehydrogenase inhibitor, is used to prevent metabolite formation with other toxic alcohol exposures. Fomepizole is recommended for DEG poisoning, though supporting clinical evidence is limited. CASE REPORT: A 31-year-old man presented after ingestion of DEG-containing brake fluid and hydrocarbon-containing "octane booster." He was noted to be clinically intoxicated, with a mildly elevated anion gap metabolic acidosis and no osmolar gap. DEG level was later found to be elevated, consistent with his ingestion. He was treated with fomepizole alone, with resolution of metabolic acidosis and clinical findings over the next 2 days. No delayed neurologic sequelae were present at 52-day follow-up. Our case provides additional evidence supporting the use of fomepizole for DEG poisoning. Consistent with other toxic alcohols, DEG poisoning, especially early presentations, may benefit from empiric fomepizole administration. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: DEG poisoning is potentially life threatening, but treatable if identified early. An ingestion can be toxic despite a normal osmolar gap, leading to false reassurance. Finally, it is rare, so emergency physicians must be made aware of its potential dangers.
Asunto(s)
Acidosis , Intoxicación , Acidosis/inducido químicamente , Acidosis/tratamiento farmacológico , Adulto , Alcohol Deshidrogenasa/uso terapéutico , Aldehído Deshidrogenasa/uso terapéutico , Antídotos/farmacología , Antídotos/uso terapéutico , Ingestión de Alimentos , Glicol de Etileno , Glicoles de Etileno , Fomepizol/uso terapéutico , Glicerol/uso terapéutico , Humanos , Masculino , Octanos/uso terapéutico , Intoxicación/terapia , Glicoles de Propileno/uso terapéutico , Pirazoles/farmacología , Pirazoles/uso terapéutico , Solventes/uso terapéuticoRESUMEN
Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum ß-lactamases. The design of novel ß-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107), and WCK 4234 (compounds 1-3, respectively), were synthesized and biochemically characterized against clinically important bacteria. Compound 3 inhibited class A, C, and D ß-lactamases with unprecedented k2/ K values against OXA carbapenemases. Compounds 1 and 2 acylated class A and C ß-lactamses rapidly but not the tested OXAs. Compounds 1-3 formed highly stable acyl-complexes as demonstrated by mass spectrometry. Crystallography revealed that 1-3 complexed with KPC-2 adopted a "chair conformation" with the sulfate occupying the carboxylate binding region. The cefepime-2 and meropenem-3 combinations were effective in murine peritonitis and neutropenic lung infection models caused by MDR Acinetobacter baumannii. Compounds 1-3 are novel ß-lactamase inhibitors that demonstate potent cross-class inhibition, and clinical studies targeting MDR infections are warranted.
Asunto(s)
Compuestos de Azabiciclo/farmacología , Compuestos Bicíclicos con Puentes/farmacología , Ciclooctanos/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Octanos/farmacología , Piperidinas/farmacología , Resistencia betalactámica/efectos de los fármacos , Inhibidores de beta-Lactamasas/farmacología , beta-Lactamasas/metabolismo , beta-Lactamas/farmacología , Animales , Compuestos de Azabiciclo/química , Compuestos de Azabiciclo/uso terapéutico , Compuestos Bicíclicos con Puentes/química , Compuestos Bicíclicos con Puentes/uso terapéutico , Ciclooctanos/química , Ciclooctanos/uso terapéutico , Sinergismo Farmacológico , Pulmón/efectos de los fármacos , Pulmón/microbiología , Ratones , Octanos/química , Octanos/uso terapéutico , Peritonitis/tratamiento farmacológico , Peritonitis/microbiología , Piperidinas/química , Piperidinas/uso terapéutico , Inhibidores de beta-Lactamasas/química , Inhibidores de beta-Lactamasas/uso terapéuticoRESUMEN
A series of novel azobicyclo[3.3.0]octane derivatives were synthesized and evaluated as dipeptidyl peptidase 4 (DPP-4) inhibitors. The effort resulted in the discovery of inhibitor 2a, which exhibited excellent efficacies in an oral glucose tolerance test. Introduction of methyl group (2j) could prolong the inhibition of serum DPP-4 activity.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/síntesis química , Hipoglucemiantes/síntesis química , Octanos/síntesis química , Octanos/uso terapéutico , Animales , Compuestos Azo/síntesis química , Compuestos Bicíclicos con Puentes/síntesis química , Dipeptidil Peptidasa 4/sangre , Dipeptidil Peptidasa 4/metabolismo , Inhibidores de la Dipeptidil-Peptidasa IV/farmacología , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Prueba de Tolerancia a la Glucosa , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Ratones , Ratones Endogámicos ICR , Octanos/farmacología , Farmacocinética , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
PURPOSE: To describe a solvent that removes silicone oil adhesions on intraocular lenses (IOLs). METHOD: The solvent O44 is a partially fluorinated alcane that dissolves silicone oil. Silicone oil adhesions on silicone and poly(methyl methacrylate) IOLs were treated with O44. The extent of silicone oil adhesions and the effectiveness of O44 were studied by gross microscopy. RESULTS: The solvent O44 removed silicone oil adhesions from both IOL types. CONCLUSION: The substance O44 may be a successful intraoperative tool to remove silicone oil IOL adhesions, avoiding IOL explantation.